Business Wire

OnProcess and Baxter Planning Forge Strategic Product and Commercial Partnership

14.7.2022 16:57:00 EEST | Business Wire | Press release

Share

OnProcess Technology (www.onprocess.com), a global pioneer powering the world’s circular service supply chains, today announced the formation of a new strategic commercial and product partnership with Baxter Planning (www.baxterplanning.com). The partnership includes joint investment in the two companies’ technology roadmaps, a commitment to integrating certain product offerings, and a combined commercial approach.

The partnership is in response to what both companies see as growing industry calls to deliver and manage best-in-class service supply chains. As a result of several macroeconomic factors - global supply chain uncertainties, growing demand for sustainable practices, increasing e-waste legislation, the continued move to servitization, as well as higher cost of goods driven by rising interest rates and inflation - both companies cite that there has never been more focus on the role that the service supply chains play.

OnProcess and Baxter Planning have aligned views around the need to speed up the digitalization across the three main functions of the service supply chain:

  • Planning (ensuring inventory levels are available in the right places to meet service-level commitments/SLAs)
  • Delivering (ensuring inventory is delivered efficiently, to customers or other end-users, according to SLAs) and
  • Recovering (ensuring that the maximum value is recovered from assets no longer required in the field, whether that inventory is unused, in need of repair/refurbishment/recycling, or for warranty recovery)

And putting Customer Experience at the heart of the service event.

The two companies recognize that to solve the complexities of the service supply chain requires a foundation built on aggregated data, and a platform that integrates and gathers that data from otherwise siloed operational sources. Only then can the three functional areas of Planning, Delivery and Recovery fully work together and provide a seamless view of the whole service supply chain. This results in smarter decisions, frictionless customer experiences, and a circular model that helps drive towards sustainability goals and targets.

With Baxter’s long-established record as a leader in the inventory planning market, and OnProcess’s reputation as a full-service provider to some of the world’s most recognised brands, the two companies have committed to further integrating their respective product offerings, such as Baxter Planning’s Prophet for service parts planning, and OnProcess’s Agora platform.

“We are excited to announce this very strategic partnership with Baxter,” said Oliver Lemanski, CEO, OnProcess. “Their deep domain expertise in service inventory planning, along with their market-leading software products, makes a natural fit with OnProcess, and in particular our technology platform Agora. We are on a mission to power the world’s circular service supply chains across a seamless process flow of Planning, Delivery and Recovery, and to do that we welcome partnerships, such as this with Baxter, to help us deliver on our promise .

“OnProcess has an enviable reputation in the service supply chain market, with some of the world’s most recognized brands as their clients,” stated Chuck Moeling, CEO, Baxter Planning. “As a best-of-breed planning provider, we see only synergy with OnProcess’s focus on Delivery and Recovery. We look forward to deepening our relationship and further developing our respective products so we can provide our mutual customers the very best the market has to offer .

About OnProcess Technology, Inc.

OnProcess supplies technology and services that power the world’s circular service supply chains. Delivering through the Agora™ platform, OnProcess streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals for many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies. For more information please visit www.onprocess.com.

About Baxter Planning

Founded in 1993, Baxter Planning was built expressly for the service supply chain. Their software is developed based on proven best practices, industry expertise, and a partnership with customers to automate inventory planning. Their Total Cost Optimization methodology replaces spreadsheets and manual processes to deliver the best service level at the lowest possible cost. As a worldwide leader in Service Supply Chain software, Baxter Planning helps customers plan billions in service parts inventory every day. For more information, visit http://www.baxterplanning.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marta Marinova
OnProcess Technology, Inc.
mmarinova@onprocess.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye